Audentes Therapeutics (BOLD) Tops Q4 EPS by 9c

Audentes Therapeutics (NASDAQ: BOLD) reported Q4 EPS of ($0.82), $0.09 better than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance